3. Clinical Data ( CLDA) is a biotechnology company. It has several late-stage compounds, including Vilazodone for depression and Stedivaze for cardiac stress. It also sells genetic tests to determine drug response. Its fiscal first-quarter loss narrowed to $14 million, or 51 cents a share, from a loss of $15 million, or 88 cents, a year earlier. Revenue grew 48%. Clinical Data's stock is expensive based on all relative valuation metrics since the company is consistently unprofitable. Still, all six analysts following Clinical Data recommend purchasing its shares.